Skip to main content

Targeting Breast Cancer Cells and Their Metastases Through Luteinizing Hormone Releasing Hormone (LHRH) Receptors Using Magnetic Nanoparticles

Buy Article:

$107.14 + tax (Refund Policy)

Primary tumors and metastases from human breast cancer xenografts are specifically targeted by luteinizing hormone releasing hormone (LHRH) conjugated to superparamagnetic iron oxide nanoparticles (SPION) and incorporated into the cells. In vitro LHRH-bound magnetic nanoparticles accumulated in a 12-fold higher concentration than magnetite particles alone. In vivo, breast to lung metastases accumulated LHRH-SPION at concentrations dependent on the number of metastatic cells, while unconjugated particles did not accumulate in lung metastases.

Keywords: HUMAN BREAST CANCER; LUTEINIZING HORMONE RELEASING HORMONE RECEPTORS; METASTASES; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES

Document Type: Short Communication

Publication date: 01 June 2005

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content